Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
55190
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "55190" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-P85898
Synonyms: CD 74 antibody; CD74 antibody; CD74 antigen; invariant polypeptide of major histocompatibility complex; class II antigen-associated; antibody; CD74 antigen antibody; CD74 molecule antibody; CD74 molecule; major histocompatibility complex; class II invariant chain antibody; CLIP antibody; DHLAG antibody; Gamma chain of class II antigens antibody; HG2A_HUMAN antibody; HLA class II histocompatibility antigen gamma chain antibody; HLA DR antigens associated invariant chain antibody; HLA DR gamma antibody; HLA-DR antigens-associated invariant chain antibody; HLA-DR-gamma antibody; HLADG antibody; HLADR antigens associated invariant chain antibody; Ia antigen associated invariant chain antibody; Ia antigen-associated invariant chain antibody; Ia associated invariant chain antibody; Ia gamma antibody; Ii antibody; Invariant polypeptide of major histocompatibility complex class II antigen associated antibody; la-gamma antibody; Major histocompatibility complex class II invariant chain antibody; MHC HLA DR gamma chain antibody; MHC HLA-DR gamma chain antibody; p33 antibody; p35 antibody; Protein 41 antibody;
Category:
Target:
Synonyms: E5510
Target:
Research Areas:
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .
Cat. No.: HY-R01748A
hsa-miR-5590-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
Cat. No.: HY-RI01747
hsa-miR-5590-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
Cat. No.: HY-RI01748A
hsa-miR-5590-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
Cat. No.: HY-R01576A
hsa-miR-5190 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
Cat. No.: HY-RI01576
hsa-miR-5190 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
Cat. No.: HY-RI01576A
hsa-miR-5190 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
Cat. No.: HY-R01747A
hsa-miR-5590-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
Cat. No.: HY-RI01747A
hsa-miR-5590-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
Cat. No.: HY-RI01748
hsa-miR-5590-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
Cat. No.: HY-P84562A
Synonyms: MCI1; LRP-8; APOER2; HSZ75190
Cat. No.: HY-P85827
Synonyms: a actin; AAT6; ACTA; ACT; ACTA3; ACTE; ACTG2; ACTH_HUMAN; Actin; Actin gamma 2 smooth muscle enteric; Actin gamma enteric smooth muscle; Actin like protein; ACTL3; ACTSG; Alpha actin 3; Alpha-actin-3; Gamma 2 actin; Gamma-2-actin; gamma-enteric smooth muscle; Smooth muscle gamma actin; Smooth muscle gamma-actin
Cat. No.: HY-P85498
Synonyms: Ala-IL-8; 77; Ser-IL-8; 72; 3 10C; 310C; AMCF 1; AMCF1; b ENAP; Bbeta thromboglobulin like protein; Beta thromboglobulin like protein; C-X-C motif chemokine 8; CXC chemokine ligand 8; CXCL 8; CXCL8; Emoctakin; GCP 1; GCP-1; GCP/IL-8 protein I; GCP/IL-8 protein II; GCP/IL-8 protein III; GCP/IL-8 protein IV; GCP/IL-8 protein V; GCP/IL-8 protein VI; GCP1; Granulocyte chemotactic protein 1; IL 8; IL-8; IL-8; 1-77; IL-8; 9-77; IL8; IL8/NAP1 form I; IL8/NAP1 form II; IL8/NAP1 form III; IL8/NAP1 form IV; IL8/NAP1 form V; IL8/NAP1 form VI; IL8_HUMAN; Inteleukin 8; Interleukin8; K 60; K60; LECT; LUCT; Lymphocyte derived neutrophil activating factor; Lymphocyte-derived neutrophil-activating factor; LYNAP; MDNCF; MDNCF-b; MDNCF-c; MONAP; Monocyte derived neutrophil activating peptide; Monocyte derived neutrophil activating protein; Monocyte derived neutrophil chemotactic factor; Monocyte-derived neutrophil chemotactic factor; Monocyte-derived neutrophil-activating peptide; NAF; NAP 1; NAP-1; NAP1; Neutrophil activating factor; Neutrophil activating peptide 1; Neutrophil activating protein 1; Neutrophil-activating factor; Neutrophil-activating protein 1; Protein 3 10C; Protein 3-10C; SCYB 8; SCYB8; Small inducible cytokine subfamily B member 8; T cell chemotactic factor; T-cell chemotactic factor; TSG 1; TSG1;
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
